The U.S. Food and Drug Administration (FDA) granted fast track designation to EG110A, EG 427‘s DNA-based therapy to treat neurogenic detrusor overactivity (NDO) — a bladder disorder that can arise from […]
The post FDA fast tracks DNA therapy for MS-related bladder issue appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com